QuidelOrtho Corp. Aktie
25,80 €
Deine Einschätzung
QuidelOrtho Corp. Aktie
Was spricht für und gegen QuidelOrtho Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von QuidelOrtho Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | -5,11 % | 6,61 % | 5,74 % | -35,50 % | -38,57 % | -65,83 % | -87,23 % |
Veeva Systems A | -1,99 % | 2,10 % | 8,86 % | 36,55 % | 24,56 % | 49,09 % | 7,66 % |
Thermo Fisher Scientific Inc. | 2,92 % | 16,54 % | 11,19 % | -15,23 % | -7,45 % | -13,33 % | 24,33 % |
Waters Corp. | 2,29 % | 12,40 % | 12,54 % | -12,14 % | -21,23 % | -1,02 % | 67,72 % |
Kommentare
News

QuidelOrtho (QDEL) Fiscal Q2 EPS Beats
QuidelOrtho (NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a

QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

QuidelOrtho Reports First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and